CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

307 papers

Showing 193-204 of total 307 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

Engineering a Second Interchain Disulfide Bond in the αβ T-Cell Receptor Constant Domain: A Powerful Strategy to Enhance Stability, Pairing Fidelity, and Therapeutic Efficacy in TCR-T Cell Therapy.

2026PubMedSupporting evidence

CD19 CAR-T cell therapy in large B-cell lymphoma: clinical evidence, resistance, toxicity, and precision strategies.

Wang C; Zhu J; Qiao J; Wang H; Liang X

Jan 1, 2026Frontiers in immunology

2026PubMedDirectly related

NF-κB/NFAT signaling contributes to B7-H3 TRuC-T cell cytotoxicity and supports a reporter platform for glioblastoma immunotherapy.

Lin J; Zhang P; Li X; Lu S; Yu Q; Zheng J; Yang J; Chen X; Wei C; Gao J; Zhao A

Jan 1, 2026Frontiers in immunology

2026PubMedDirectly related

T-cell receptor-engineered T-cell therapy using a glypican-3-specific TCR derived from a hepatoblastoma vaccine responder for HLA-A2-positive glypican-3-expressing cancers.

Terada T; Suzuki T; Ohnuki K; Yoshikawa T; Shimomura M; Shoda K; Amaishi Y; Takeichi K; Kudo M; Sugimoto M; Kobayashi S; Takenouchi K; Tsukamoto N; Gotohda N; Okamoto S; Nakatsura T

Jan 1, 2026Cancer letters

2026PubMedSupporting evidence

Hattrick against Lymphoma with Trispecific CAR T Cells.

Merz M; Luttwak E

Jan 1, 2026Blood cancer discovery

2026PubMedDirectly related

Nano meets CAR-T: A new era in cancer immunotherapy.

Ibrahim A; Nasr M

Jan 1, 2026Biochimica et biophysica acta. Reviews on cancer

2026PubMedDirectly related

In vivo CAR-T therapy: The shift from ex vivo culturing to direct in situ immune reprogramming.

Gopalakrishnan J; Rathod B; Puri S

Jan 1, 2026International immunopharmacology

2026PubMedDirectly related

Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells.

Zi G; Zhang L; Zhou L; Liu X; Wang L; Zhou R; Zheng P; Wei J; Chen X; Wei S

Jan 1, 2026Signal transduction and targeted therapy

2026PubMedDirectly related

Emerging Landscape of CAR-T Cell Therapy in Colon Cancer: Mechanistic Insights, Clinical Advances, Challenges, and Future Directions.

Raza A; Raza MA; Khan J; Ajazuddin

Jan 1, 2026Pathology, research and practice

2026PubMedDirectly related

Lipid nanoparticle-based multi-scale systemic immune programming for cancer therapy.

Lin X; Li Y; Shen X; Li B; Xu Y

Jan 1, 2026Molecular therapy : the journal of the American Society of Gene Therapy

2026PubMedDirectly related

Engineered immune cells and extracellular vesicles target tumour microenvironment barriers in solid tumour immunotherapy.

Zhou X; Chen S; Liang J

Jan 1, 2026Discover oncology

2026PubMedDirectly related

Cytokine circuitries as determinants of response, resistance, and toxicity across cancer immunotherapy platforms.

Mukherjee A

Jan 1, 2026Cytokine & growth factor reviews